Business Context and Reporting Period
Akebia Therapeutics, Inc. filed this Form 8-K on July 25, 2016, to disclose the execution of a Third Amendment to its headquarters lease. The Company is a biopharmaceutical firm based in Cambridge, Massachusetts.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details specific lease terms:
- Monthly Rent: Approximately $34,714.17 for 5,951 rentable square feet.
- Commencement: Payments begin approximately December 1, 2016, pending landlord work completion.
- Lease Term: Five years with an option to extend for an additional two years.
- Landlord Contribution: $89,265.00 for leasehold improvements.
- Escalations: Annual rent increases apply commencing December 1, 2017.
Material Changes
The material change is the extension of the existing lease for the Company's office, research, and laboratory space at 245 First Street, Cambridge, Massachusetts. This amendment modifies the original lease dated December 3, 2013.
Outlook and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks beyond the standard lease obligations. The commencement of rent payments is contingent upon the completion of work by the Landlord.
Investor Verification Points
- Verify the impact of the new monthly rent obligation on the Company's operating cash flow.
- Confirm the status of the leasehold improvements funded by the $89,265.00 landlord contribution.
- Monitor the actual delivery date of the premises to determine the precise start of rent payments and escalation schedules.